Kamran Mazaheri Kalahroudi - Department of Biochemistry and Biophysics, School of Biological Sciences, Varamin-Pishva Branch, Islamic Azad University, Varamin, Iran
Hassan Sahebjamee - Department of Biochemistry and Biophysics, School of Biological Sciences, Varamin-Pishva Branch, Islamic Azad University, Varamin, Iran

The μ opioid receptor (MOR) was identified pharmacologically and biochemically in binding studies forty years ago, its structure, function, and true complexity only have emerged after its cloning in 1993 [1]. An agonist is a chemical that binds to a receptor and activates the receptor to produce a biological response. Receptors can be activated by endogenous agonists (such as hormones and neurotransmitters) or exogenous agonists (such as drugs), lead to biological response. A physiological agonist is a substance that makes the same responses but does not bind to the same receptor [2]. New findings that extend the conventional definition of pharmacology demonstrate that ligands can behave as agonist and antagonists at the same receptor, depending on effector pathways or tissue type [3]. The receivers have different types (such as alpha-1 and alpha-2, etc.). Thebaine known as codeine methyl enol ether. The synthetic enantiomer (+)-thebaine does show analgesic effects apparently mediated through opioid receptors, unlike the inactive natural enantiomer (−) thebaine [4]. Docking is a method in structure-based design for building or optimizing leader ligands and optimizing them. The results of docking can be used to find inhibitors for target proteins [5]. The methods for designing drug with computer are divided into Dock recepotor, Ligand and De Novo Design approach [6].